KALAMAZOO, Mich., December 27, 2017: Medizone International, Inc. (OTCQB: MZEI) announced today the Company’s management will be attending the J.P. Morgan 36th Annual Healthcare Conference in San Francisco January 8th through 11th. Attending the conference will be Medizone’s CEO David Dodd and Medizone’s Chairman of the Board David Esposito. The company will be meeting with potential business partners and investment partners in support of the commercial development of AsepticSure®.
Medizone International, Inc., CEO David Dodd commented, “AsepticSure® represents a superior disinfectant technology compared to conventional systems or practices, providing over a thousand-times improvement in the reduction of pathogens, validated to disinfect to the sterilization standard of a 6-log reduction, representing greater than 99.9999% reduction. To-date, our data demonstrates that AsepticSure® achieves 100% kill on 100% of surfaces, 100% of the time on 100% of pathogens – what we call the, ‘AsepticSure® 100% Rule’. With the product approved for widespread commercialization, we are actively discussing with potential business partners and investment partners various options to achieve and grow AsepticSure® into the standard for disinfection and decontamination across multiple markets worldwide.”
About Medizone International, Inc.
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released the AsepticSure® System for use in multiple markets worldwide.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
For more information, visit:
Email: [email protected]